BCMA-targeted therapies, including bispecific T-cell engagers, hold promise for generating deep and durable responses in multiple myeloma (MM) and merit investigation in earlier lines of treatment, including in newly diagnosed MM, Italian researchers write in a review article published in the January 2021 issue of Expert Opinion on Biological Therapy.
As off-the-shelf therapies that do not depend on ex vivo manipulation of patients’ cells, bispecific antibody constructs offer two potential advantages over CAR T-cell therapy, write authors Massimo Martino and Annalisa Paviglianiti of the Grande Ospedale Metropolitano in Reggio Calabria, Italy: immediate availability for treatment initiation and ability to be administered in the community.
Currently rhe most critical limitation of these constructs, according to the authors, is their short half-life, which necessitates prolonged intravenous infusion. In an effort to overcome this limitation, several clinical trials are currently underway to investigate bispecific antibody constructs with longer half-lives.
Martino M, Paviglianiti A. An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma [published online ahead of print, 2021 Jan 13]. Expert Opin Biol Ther. 2021;1-10. doi:10.1080/14712598.2021.1872540
Tags: BCMA, multiple myeloma, BCMA therapies